A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study

Alberto S. Pappo, Gilles Vassal, John J. Crowley, Vanessa Bolejack, Pancras C W Hogendoorn, Rashmi Chugh, Marc Ladanyi, Joseph F. Grippo, Georgina Dall, Arthur P. Staddon, Sant P. Chawla, Robert G. Maki, Dejka M. Araujo, Birgit Geoerger, Kristen Ganjoo, Neyssa Marina, Jean Yves Blay, Scott M. Schuetze, Warren A. Chow, Lee J. Helman

Research output: Contribution to journalArticle

Abstract

BACKGROUND Insulin-like growth factor-1 receptor (IGF-1R) is implicated in the pathogenesis of rhabdomyosarcoma (RMS), osteosarcoma (OS), and synovial sarcoma (SS). The authors conducted a multi-institutional phase 2 trial of the monoclonal antibody R1507 in patients with various subtypes of recurrent or refractory sarcomas. METHODS Eligibility criteria included age ≥2 years and a diagnosis of recurrent or refractory RMS, OS, SS, and other soft tissue sarcomas. Patients received a weekly dose of 9 mg/kg R1507 intravenously. The primary endpoint was the best objective response rate using World Health Organization criteria. Tumor imaging was performed every 6 weeks × 4 and every 12 weeks thereafter. RESULTS From December 2007 through August 2009, 163 eligible patients from 33 institutions were enrolled. The median patient age was 31 years (range, 7-85 years). Histologic diagnoses included OS (n = 38), RMS (n = 36), SS (n = 23), and other sarcomas (n = 66). The overall objective response rate was 2.5% (95% confidence interval, 0.7%-6.2%). Partial responses were observed in 4 patients, including 2 patients with OS, 1 patient with RMS, and 1 patient with alveolar soft part sarcoma. Four additional patients (3 with RMS and 1 with myxoid liposarcoma) had a ≥50% decrease in tumor size that lasted for

Original languageEnglish (US)
Pages (from-to)2448-2456
Number of pages9
JournalCancer
Volume120
Issue number16
DOIs
StatePublished - Aug 15 2014
Externally publishedYes

Fingerprint

R-1507 monoclonal antibody
Somatomedin Receptors
Synovial Sarcoma
Rhabdomyosarcoma
Osteosarcoma
Sarcoma
Monoclonal Antibodies
Research
Alveolar Soft Part Sarcoma
Myxoid Liposarcoma

Keywords

  • IGF-1R
  • insulin-like growth factor
  • SARC
  • sarcoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas : Results of a Sarcoma Alliance for Research Through Collaboration study. / Pappo, Alberto S.; Vassal, Gilles; Crowley, John J.; Bolejack, Vanessa; Hogendoorn, Pancras C W; Chugh, Rashmi; Ladanyi, Marc; Grippo, Joseph F.; Dall, Georgina; Staddon, Arthur P.; Chawla, Sant P.; Maki, Robert G.; Araujo, Dejka M.; Geoerger, Birgit; Ganjoo, Kristen; Marina, Neyssa; Blay, Jean Yves; Schuetze, Scott M.; Chow, Warren A.; Helman, Lee J.

In: Cancer, Vol. 120, No. 16, 15.08.2014, p. 2448-2456.

Research output: Contribution to journalArticle

Pappo, AS, Vassal, G, Crowley, JJ, Bolejack, V, Hogendoorn, PCW, Chugh, R, Ladanyi, M, Grippo, JF, Dall, G, Staddon, AP, Chawla, SP, Maki, RG, Araujo, DM, Geoerger, B, Ganjoo, K, Marina, N, Blay, JY, Schuetze, SM, Chow, WA & Helman, LJ 2014, 'A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study', Cancer, vol. 120, no. 16, pp. 2448-2456. https://doi.org/10.1002/cncr.28728
Pappo, Alberto S. ; Vassal, Gilles ; Crowley, John J. ; Bolejack, Vanessa ; Hogendoorn, Pancras C W ; Chugh, Rashmi ; Ladanyi, Marc ; Grippo, Joseph F. ; Dall, Georgina ; Staddon, Arthur P. ; Chawla, Sant P. ; Maki, Robert G. ; Araujo, Dejka M. ; Geoerger, Birgit ; Ganjoo, Kristen ; Marina, Neyssa ; Blay, Jean Yves ; Schuetze, Scott M. ; Chow, Warren A. ; Helman, Lee J. / A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas : Results of a Sarcoma Alliance for Research Through Collaboration study. In: Cancer. 2014 ; Vol. 120, No. 16. pp. 2448-2456.
@article{344c04e8fee64bd48382bb208c87d242,
title = "A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance for Research Through Collaboration study",
abstract = "BACKGROUND Insulin-like growth factor-1 receptor (IGF-1R) is implicated in the pathogenesis of rhabdomyosarcoma (RMS), osteosarcoma (OS), and synovial sarcoma (SS). The authors conducted a multi-institutional phase 2 trial of the monoclonal antibody R1507 in patients with various subtypes of recurrent or refractory sarcomas. METHODS Eligibility criteria included age ≥2 years and a diagnosis of recurrent or refractory RMS, OS, SS, and other soft tissue sarcomas. Patients received a weekly dose of 9 mg/kg R1507 intravenously. The primary endpoint was the best objective response rate using World Health Organization criteria. Tumor imaging was performed every 6 weeks × 4 and every 12 weeks thereafter. RESULTS From December 2007 through August 2009, 163 eligible patients from 33 institutions were enrolled. The median patient age was 31 years (range, 7-85 years). Histologic diagnoses included OS (n = 38), RMS (n = 36), SS (n = 23), and other sarcomas (n = 66). The overall objective response rate was 2.5{\%} (95{\%} confidence interval, 0.7{\%}-6.2{\%}). Partial responses were observed in 4 patients, including 2 patients with OS, 1 patient with RMS, and 1 patient with alveolar soft part sarcoma. Four additional patients (3 with RMS and 1 with myxoid liposarcoma) had a ≥50{\%} decrease in tumor size that lasted for",
keywords = "IGF-1R, insulin-like growth factor, SARC, sarcoma",
author = "Pappo, {Alberto S.} and Gilles Vassal and Crowley, {John J.} and Vanessa Bolejack and Hogendoorn, {Pancras C W} and Rashmi Chugh and Marc Ladanyi and Grippo, {Joseph F.} and Georgina Dall and Staddon, {Arthur P.} and Chawla, {Sant P.} and Maki, {Robert G.} and Araujo, {Dejka M.} and Birgit Geoerger and Kristen Ganjoo and Neyssa Marina and Blay, {Jean Yves} and Schuetze, {Scott M.} and Chow, {Warren A.} and Helman, {Lee J.}",
year = "2014",
month = "8",
day = "15",
doi = "10.1002/cncr.28728",
language = "English (US)",
volume = "120",
pages = "2448--2456",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "16",

}

TY - JOUR

T1 - A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas

T2 - Results of a Sarcoma Alliance for Research Through Collaboration study

AU - Pappo, Alberto S.

AU - Vassal, Gilles

AU - Crowley, John J.

AU - Bolejack, Vanessa

AU - Hogendoorn, Pancras C W

AU - Chugh, Rashmi

AU - Ladanyi, Marc

AU - Grippo, Joseph F.

AU - Dall, Georgina

AU - Staddon, Arthur P.

AU - Chawla, Sant P.

AU - Maki, Robert G.

AU - Araujo, Dejka M.

AU - Geoerger, Birgit

AU - Ganjoo, Kristen

AU - Marina, Neyssa

AU - Blay, Jean Yves

AU - Schuetze, Scott M.

AU - Chow, Warren A.

AU - Helman, Lee J.

PY - 2014/8/15

Y1 - 2014/8/15

N2 - BACKGROUND Insulin-like growth factor-1 receptor (IGF-1R) is implicated in the pathogenesis of rhabdomyosarcoma (RMS), osteosarcoma (OS), and synovial sarcoma (SS). The authors conducted a multi-institutional phase 2 trial of the monoclonal antibody R1507 in patients with various subtypes of recurrent or refractory sarcomas. METHODS Eligibility criteria included age ≥2 years and a diagnosis of recurrent or refractory RMS, OS, SS, and other soft tissue sarcomas. Patients received a weekly dose of 9 mg/kg R1507 intravenously. The primary endpoint was the best objective response rate using World Health Organization criteria. Tumor imaging was performed every 6 weeks × 4 and every 12 weeks thereafter. RESULTS From December 2007 through August 2009, 163 eligible patients from 33 institutions were enrolled. The median patient age was 31 years (range, 7-85 years). Histologic diagnoses included OS (n = 38), RMS (n = 36), SS (n = 23), and other sarcomas (n = 66). The overall objective response rate was 2.5% (95% confidence interval, 0.7%-6.2%). Partial responses were observed in 4 patients, including 2 patients with OS, 1 patient with RMS, and 1 patient with alveolar soft part sarcoma. Four additional patients (3 with RMS and 1 with myxoid liposarcoma) had a ≥50% decrease in tumor size that lasted for

AB - BACKGROUND Insulin-like growth factor-1 receptor (IGF-1R) is implicated in the pathogenesis of rhabdomyosarcoma (RMS), osteosarcoma (OS), and synovial sarcoma (SS). The authors conducted a multi-institutional phase 2 trial of the monoclonal antibody R1507 in patients with various subtypes of recurrent or refractory sarcomas. METHODS Eligibility criteria included age ≥2 years and a diagnosis of recurrent or refractory RMS, OS, SS, and other soft tissue sarcomas. Patients received a weekly dose of 9 mg/kg R1507 intravenously. The primary endpoint was the best objective response rate using World Health Organization criteria. Tumor imaging was performed every 6 weeks × 4 and every 12 weeks thereafter. RESULTS From December 2007 through August 2009, 163 eligible patients from 33 institutions were enrolled. The median patient age was 31 years (range, 7-85 years). Histologic diagnoses included OS (n = 38), RMS (n = 36), SS (n = 23), and other sarcomas (n = 66). The overall objective response rate was 2.5% (95% confidence interval, 0.7%-6.2%). Partial responses were observed in 4 patients, including 2 patients with OS, 1 patient with RMS, and 1 patient with alveolar soft part sarcoma. Four additional patients (3 with RMS and 1 with myxoid liposarcoma) had a ≥50% decrease in tumor size that lasted for

KW - IGF-1R

KW - insulin-like growth factor

KW - SARC

KW - sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84905586194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905586194&partnerID=8YFLogxK

U2 - 10.1002/cncr.28728

DO - 10.1002/cncr.28728

M3 - Article

C2 - 24797726

AN - SCOPUS:84905586194

VL - 120

SP - 2448

EP - 2456

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 16

ER -